NYSE - Novavax, Inc.

График котировок Novavax, Inc.


Добавить в список сравнения Добавить в список сравнения
Добавить в список отслеживания Добавить в список отслеживания
Добавить в портфель Добавить в портфель

Основные параметры

P/S 78.59
P/BV 141.48
EV/EBITDA -215.3
EBITDA -0.0687
Цена ао 239.25

Все параметры ⇨

Оценка

Недооценка

Название Значение Оценка
P/S 78.59 1
P/BV 141.48 1
P/E 0
EV/EBITDA -215.3 10

Эффективность

Название Значение Оценка
ROA, % -8.19 1
ROE, % -468.16 1

Дивиденды

Название Значение Оценка
Div yield, % 0
DSI 0 0

Долг

Название Значение Оценка
Долг/EBITDA 0

Импульс роста

Название Значение Оценка
Рост прибыли, % 0 0
Рост цены акции, % 0 0
Рост дивидендов, % 0 0

Основные владельцы

Institutions Объем Доля, %
Waverton Investment Management Ltd 470000 0.06
Marlborough Fund Managers Limited 434000 0.05
T&D Asset Management Co Ltd 45800 0.01
Lazard Asset Management LLC 3703500 0.46
Hanwha Asset Management Co Ltd 239200 0.03
BlackRock Fund Advisors 16155572 2.01
Victory Capital Management Inc. 38400 0
Cornèr Banca SA 220000 0.03
Invesco Capital Management LLC 737441 0.09
Azimut Investments S.A. 75000 0.01
Edmond de Rothschild Asset Management (Lux) 76693 0.01
WisdomTree Asset Management Inc 5946300 0.74
Morningstar Inv Management Australia Ltd 513564 0.06
BlackRock Advisors (UK) Limited 1763108 0.22
Great-West Capital Management LLC 2432200 0.3
Eastspring Investments (Singapore) Ltd 73000 0.01
Mellon Investments Corporation 30853 0
Northern Trust Investments Inc 1328938 0.17
SSGA Funds Management Inc 1559800 0.19
USAA Mutual Funds 435000 0.05
Nikko Asset Management Asia Limited 130100 0.02
T&D Asset Management Co Ltd 45800 0.01
Lemanik Invest S.A. 370000 0.05
Lattice Strategies LLC 94800 0.01
JP Morgan Asset Management (UK) Ltd 366700 0.05
Connor Clark & Lunn Financial Group 350200 0.04
American Century Investment Management, Inc 120600 0.01

Содержится в ETF

ETF Доля, % Доходность за год, % Дивиденды, %
Vanguard Russell 2000 Value ETF 0.78 43.95 1.27
ETFMG Treatments Testing and Advancements ETF 6.08 0.81
iShares Russell 2000 Value ETF 0.76 39.65 1.35
iShares Morningstar Small-Cap ETF 1.32 35.30 1.13
AGFiQ US Market Neutral Momentum Fund 1.13 -16.42 2.58
ProShares UltraPro Russell2000 0.27 80.24 0.15
iShares Russell 2000 ETF 0.52 48.90 0.90
SPDR S&P Biotech ETF 1.62 58.75 0.19
ProShares Ultra Russell2000 0.32 83.13 0.05
iShares ESG MSCI USA Small-Cap ETF 0.32 49.22 0.89
VanEck Vectors Biotech ETF 5.19 27.37 0.34
First Trust Mid Cap Growth AlphaDEX Fund 0.87 50.49 0.24
Direxion Daily S&P Biotech Bull 3x Shares 1.1 99.57 1.04
Principal Healthcare Innovators Index ETF 1.79 61.80 0.34
BNY Mellon US Small Cap Core Equity ETF 0.45 0.74
Virtus LifeSci Biotech Clinical Trials ETF 0.9 51.04 0.79
ProShares Hedge Replication 0.12 14.51 0.08
Invesco PureBetaSM MSCI USA Small Cap ETF 0.32 47.95 1.29
Vanguard Small Cap Value ETF 0.44 33.55 1.47
Vanguard Russell 2000 ETF 0.51 49.11 0.82

Похожие компании

Описание Novavax, Inc.

Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. It has a partnership agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.